Private Equity Firms to Acquire PPD for $3.9 Billion
The CRO Pharmaceutical Product Development (PPD) will be acquired by the Carlyle Group and Hellman and Friedman in a deal valued at approximately $3.9 billion. PPD shareholders will receive $33.25 per share in cash, and PPD will become a privately held company after completion of the transaction.
The CRO Pharmaceutical Product Development (PPD) will be acquired by the Carlyle Group and Hellman and Friedman in a deal valued at approximately $3.9 billion. PPD shareholders will receive $33.25 per share in cash, and PPD will become a privately held company after completion of the transaction. PPD employs more than 11,000 people worldwide and provides contract preclinical and clinical development services to the pharmaceutical and biotechnology sectors.
The Carlyle Group is a global alternative asset manager, and Hellman and Friedman is a private equity firm. Funding for the deal will come from the two companies, along with external debt financing commitments provided by Credit Suisse, JP Morgan, Goldman Sachs, and UBS. The transaction is expected to close in the fourth quarter of 2011.
“Fred Eshelman and PPD’s management team have built a leading and extremely high-quality global research and services organization that will continue to help pharmaceutical and biotech companies develop new drugs at lower costs,” said Karen H. Bechtel, managing director and head of the healthcare group at Carlyle, in a press release. “We look forward to helping expand and enhance PPD’s platform and broad spectrum of therapeutic expertise.”
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
